Enzyme-Activated Collagen Matrices for Controlled Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tissue matrices for healing and regeneration lack the ability to control matrix degradation kinetics, leading to rapid degradation and poor tissue integration upon implantation, resulting in subpar healing outcomes.
Innovation Solution
A method of preparing enzyme-activated tissue matrices by incorporating deactivated matrix metalloproteinases (MMPs) into collagen-based matrices, which are then reactivated by metal ions in the body to release matrikines, facilitating controlled tissue degradation and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If tissue matrices are used for healing and regeneration, then tissue repair is facilitated, but the matrices degrade rapidly leading to poor tissue integration
Solution Approach 1:
MMPs are incorporated into the tissue matrix in a deactivated form before implantation. The deactivating agent is pre-loaded into the matrix structure, ensuring that the enzyme remains inactive during storage and handling. This preliminary deactivation prevents premature degradation while allowing controlled activation later in the body
Solution Approach 2:
The patent changes the chemical state of MMPs from active to deactivated form by introducing a deactivating agent. This parameter change (activation state) allows the matrix to maintain structural integrity during storage and implantation, then transition to active degradation when needed. The deactivation/reactivation cycle provides temporal control over the degradation process
2Reliability
If MMPs are incorporated into tissue matrices to control degradation, then tissue integration is improved, but uncontrolled enzyme activity causes premature matrix breakdown
Solution Approach 1:
A deactivating agent serves as an intermediary between the MMP enzyme and the collagen matrix. This intermediary component binds to or inhibits the MMP, preventing it from acting on the matrix structure during storage and implantation. The deactivating agent mediates the interaction by temporarily blocking enzyme activity while maintaining the enzyme's presence in the matrix
Solution Approach 2:
The deactivating agent applies preliminary anti-action to the MMP enzyme by inhibiting its proteolytic activity before the enzyme can degrade the matrix. This preemptive inhibition protects the matrix structure during critical periods of storage and implantation, ensuring structural stability until controlled activation is desired
3Duration of action of stationary object
If deactivated MMPs are used in tissue matrices, then controlled degradation is achieved, but the device complexity increases
Solution Approach 1:
The patent merges multiple components (collagen matrix, MMP enzyme, and deactivating agent) into a single integrated tissue matrix product. Rather than requiring separate application of enzyme and matrix, all components are combined during manufacturing, simplifying the final product while enabling controlled degradation through the built-in deactivation mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables controlled tissue matrix degradation, enhancing healing processes, tissue integration, and regeneration by modulating MMP activity, thereby improving the efficacy of tissue repair and regeneration.
Implementation Method 1
contacting the matrix with a composition containing an enzyme, wherein the composition containing an enzyme further contains a deactivating agent for reducing the activity of the enzyme
Implementation Method 2
The deactivated MMPs can be automatically re-activated upon implantation into animal or human patients, resulting in the release of matrikines
Implementation Method 3
a method for preparing a tissue matrix composition is provided. The method comprises selecting a collagen-based tissue matrix, and contacting the matrix with a composition containing an enzyme
Data Source
AI summary
Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.